Pervaiz Naveed, Mehmood Rashid, Aithabathula Ravi Varma, Kathuria Ishita, Ahn WonMo, Le Britney-Thuy, Kim Ki-Suk, Singh Udai P, Csanyi Gabor, Singla Bhupesh
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA.
Department of Hematology, St. Jude Children's Hospital, Memphis, TN, USA.
Life Sci. 2025 Jan 15;361:123315. doi: 10.1016/j.lfs.2024.123315. Epub 2024 Dec 13.
Recent smooth muscle cell (SMC)-lineage tracing and single-cell RNA sequencing (scRNA-seq) experiments revealed a significant role of SMC-derived cells in atherosclerosis development. Further, thrombospondin-1 (TSP1), a matricellular protein, and activation of its receptor cluster of differentiation (CD) 47 have been linked with atherosclerosis. However, the role of vascular SMC TSP1-CD47 signaling in regulating VSMC phenotype and atherogenesis remains unknown.
We investigated the role of SMC CD47 activation by TSP1 in regulating VSMC phenotype and atherosclerosis development using various in vitro cell-based assays, molecular biological techniques, immunohistological approaches, reanalysis of publicly available scRNA-seq data, and cell-specific knockout mice.
We observed elevated TSP1 expression in human atherosclerotic vascular tissues and VSMCs. TSP1-treated VSMCs exhibited decreased expression of contractile SMC markers (ACTA2, CNN1, and TAGLN) and increased proliferation. Additional experiments and reanalysis of the scRNA-seq dataset showed CD47 as the major TSP1 receptor in VSMCs, with its expression increased in SMC-derived modulated cells of murine atherosclerotic arteries. Knockdown of CD47 gene in human VSMCs upregulated expression of contractile SMC markers and abrogated TSP1's effects on these genes. SMC-specific Cd47 deletion in mice suppressed atherosclerotic lesion formation, reduced macrophage accumulation, and decreased necrotic area. However, no significant differences were observed in weight gain, liver and adipose tissue mass, plasma total cholesterol, and fasting blood glucose between control and SMC-restricted Cd47-deficient mice. Further experiments demonstrated increased efferocytosis of apoptotic CD47-silenced VSMCs by macrophages.
These findings suggest that CD47 plays a crucial role in regulating VSMC phenotype, and SMC-specific-Cd47 deletion suppresses atherosclerosis.
VSMC phenotypic switching contributes to atherosclerosis development. The present study reports the novel observations that Cd47 levels are upregulated in phenotypically modulated SMCs within atherosclerotic arteries and targeted deletion of Cd47 specifically in SMCs attenuates atherosclerosis. Mechanistic in vitro investigations further showed that TSP1-CD47 signaling regulates VSMC phenotype. Therefore, targeting SMC CD47 represents a promising therapeutic target to suppress atherogenesis.
最近的平滑肌细胞(SMC)谱系追踪和单细胞RNA测序(scRNA-seq)实验揭示了SMC衍生细胞在动脉粥样硬化发展中的重要作用。此外,血小板反应蛋白-1(TSP1),一种基质细胞蛋白,及其分化簇(CD)47受体的激活与动脉粥样硬化有关。然而,血管SMC TSP1-CD47信号在调节血管平滑肌细胞(VSMC)表型和动脉粥样硬化发生中的作用仍不清楚。
我们使用各种基于细胞的体外试验、分子生物学技术、免疫组织学方法、对公开可用的scRNA-seq数据进行重新分析以及细胞特异性敲除小鼠,研究了TSP1激活SMC CD47在调节VSMC表型和动脉粥样硬化发展中的作用。
我们观察到人类动脉粥样硬化血管组织和VSMC中TSP1表达升高。TSP1处理的VSMC表现出收缩性SMC标志物(ACTA2、CNN1和TAGLN)的表达降低和增殖增加。对scRNA-seq数据集的进一步实验和重新分析表明,CD47是VSMC中主要的TSP1受体,其在小鼠动脉粥样硬化动脉的SMC衍生的调节细胞中的表达增加。在人类VSMC中敲低CD47基因可上调收缩性SMC标志物的表达,并消除TSP1对这些基因的影响。小鼠中SMC特异性Cd47缺失可抑制动脉粥样硬化病变形成,减少巨噬细胞积聚,并减少坏死面积。然而,对照小鼠和SMC特异性Cd47缺陷小鼠在体重增加、肝脏和脂肪组织质量、血浆总胆固醇和空腹血糖方面没有观察到显著差异。进一步的实验表明,巨噬细胞对凋亡的CD47沉默VSMC的吞噬作用增加。
这些发现表明,CD47在调节VSMC表型中起关键作用,SMC特异性Cd47缺失可抑制动脉粥样硬化。
VSMC表型转换有助于动脉粥样硬化的发展。本研究报告了新的观察结果,即动脉粥样硬化动脉内表型调节的SMC中Cd47水平上调,并且在SMC中特异性靶向缺失Cd47可减轻动脉粥样硬化。体外机制研究进一步表明,TSP1-CD47信号调节VSMC表型。因此,靶向SMC CD47代表了一种有前景的抑制动脉粥样硬化发生的治疗靶点。